Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 894

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 894
---
                                                                     | ​ | ​ | ​                  | ​ |     762 | ​ | ​ | ​ | ​    | ​ |     446 | ​ | ​ |
| Accumulated other comprehensive loss                                                                                                                                                                                                                                                           | ​ | ​ | ​                  | ​ |       — | ​ | ​ | ​ | ​    | ​ |     -24 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                                            | ​ | ​ | ​                  | ​ | -62,839 | ​ | ​ | ​ | ​    | ​ | -45,492 | ​ | ​ |
| Total stockholders’ deficit                                                                                                                                                                                                                                                                    | ​ | ​ | ​                  | ​ | -62,058 | ​ | ​ | ​ | ​    | ​ | -45,051 | ​ | ​ |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit                                                                                                                                                                                                           | ​ | ​ | ​                  | $ |  27,001 | ​ | ​ | ​ | ​    | $ |  45,097 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-91

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Statements of Operations and Comprehensive Loss
(Amounts in thousands, except share and per share amounts)

| ​                                                                        
 ​                                                                        | ​ 
 ​ | ​ 
 ​ | For the Year Ended December 31, 
 2023                            |   |            |   | ​ | ​ | 2022 |   |            |   | ​ 
 ​ |
|:-------------------------------------------------------------------------|:--|:--|:--------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Operating expenses:                                                      | ​ | ​ | ​                               | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Research and development                                                 | ​ | ​ | ​                               | $ |     15,866 | ​ | ​ | ​ | ​    | $ |     18,466 | ​ | ​ |
| General and administrative                                               | ​ | ​ | ​                               | ​ |      2,799 | ​ | ​ | ​ | ​    | ​ |      2,727 | ​ | ​ |
| Total operating expenses                                                 | ​ | ​ | ​                               | ​ |     18,665 | ​ | ​ | ​ | ​    | ​